董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 王思振 | 男 | Chief Executive Officer, Director and Chairman of the Board | 46 | 未披露 | 8972.36 | 2023-05-12 |
| Shan Fu | 男 | Director | 55 | 未披露 | 未持股 | 2023-05-12 |
| 阎海 | 男 | Chief Scientific Officer and Director | 55 | 未披露 | 3315.30 | 2023-05-12 |
| Xia Wu | 女 | Director | 41 | 未披露 | 未持股 | 2023-05-12 |
| Dian Kang | 男 | Independent Director | 74 | 未披露 | 未持股 | 2023-05-12 |
| Webster Cavenee | 男 | Independent Director | 71 | 未披露 | 未持股 | 2023-05-12 |
| Wing Kee Lau | 男 | Independent Director | 58 | 未披露 | 未持股 | 2023-05-12 |
| Chao Tang | 男 | Director | 64 | 未披露 | 未持股 | 2023-05-12 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 王思振 | 男 | Chief Executive Officer, Director and Chairman of the Board | 46 | 未披露 | 8972.36 | 2023-05-12 |
| 徐策 | 男 | Chief Financial Officer | 41 | 未披露 | 未持股 | 2023-05-12 |
| 阎海 | 男 | Chief Scientific Officer and Director | 55 | 未披露 | 3315.30 | 2023-05-12 |
| 焦宇辰 | 男 | Chief Technology Officer | 45 | 未披露 | 708.20 | 2023-05-12 |
| 胡云富 | 男 | Chief Medical Officer | 60 | 未披露 | 未持股 | 2023-05-12 |
| 张凤玲 | 女 | Vice President | 65 | 未披露 | 未持股 | 2023-05-12 |
董事简历
中英对照 | 中文 | 英文- 王思振
-
王思振具有丰富的跨学科创业经验和企业管理能力，在互联网通信、金融和生物医药行业拥有十八年的经验。曾创立著名企业——iTalkBB，其业务覆盖全球数百万用户，成为北美和澳洲华人地区互联网通讯第一品牌。曾在金融业服务七年，任职公司包括Capital One和 GD Capital。巴黎高等商学院MBA。
Sizhen Wang,is Genetron Holdings Limited co-founder and has served as Genetron Holdings Limited Chief Executive Officer since May 2015. Mr. Wang has served as Genetron Holdings Limited Director since April 2018, and as Genetron Holdings Limited Chairman of the Board since 2021. Prior to founding Genetron Holdings Limited Company, Mr. Wang co-founded iTalkBB in 2004, a company providing voice, TV, data and mobile communication services globally and served as executive vice president until September 2013. He led iTalkBB to enter America's VoIP residential service market and expand its business to Canada, Australia, Singapore and China over eight years and made iTalkBB to become the biggest VoIP and IPTV service provider for overseas Chinese. He previously spent seven years in finance industry, where he gained valuable experience working for Capital One and GD Capital. Mr. Wang received his bachelor's degree in economics from the Central University of Finance and Economics in 1995 and his M.B.A. degree from the HEC Paris School of Management in 2000. - 王思振具有丰富的跨学科创业经验和企业管理能力，在互联网通信、金融和生物医药行业拥有十八年的经验。曾创立著名企业——iTalkBB，其业务覆盖全球数百万用户，成为北美和澳洲华人地区互联网通讯第一品牌。曾在金融业服务七年，任职公司包括Capital One和 GD Capital。巴黎高等商学院MBA。
- Sizhen Wang,is Genetron Holdings Limited co-founder and has served as Genetron Holdings Limited Chief Executive Officer since May 2015. Mr. Wang has served as Genetron Holdings Limited Director since April 2018, and as Genetron Holdings Limited Chairman of the Board since 2021. Prior to founding Genetron Holdings Limited Company, Mr. Wang co-founded iTalkBB in 2004, a company providing voice, TV, data and mobile communication services globally and served as executive vice president until September 2013. He led iTalkBB to enter America's VoIP residential service market and expand its business to Canada, Australia, Singapore and China over eight years and made iTalkBB to become the biggest VoIP and IPTV service provider for overseas Chinese. He previously spent seven years in finance industry, where he gained valuable experience working for Capital One and GD Capital. Mr. Wang received his bachelor's degree in economics from the Central University of Finance and Economics in 1995 and his M.B.A. degree from the HEC Paris School of Management in 2000.
- Shan Fu
-
Shan Fu自业务合并完成以来，一直担任公司董事。 自2013年10月起，傅先生一直担任Vivo Capital LLC的执行合伙人，联席首席执行官和大中华区首席执行官，该公司主要投资于生物技术和医疗保健领域。 诺华生物技术有限公司董事 纳斯达克（Nasdaq）：SVA自2018年7月起担任TOT BIOPHARM International Co.Ltd.的董事。 自2016年1月起（HKSE：01875）担任InnoCare Pharma Ltd.的董事。 自2018年2月（HKSE：09969）开始。傅先生在2008年6月至2013年10月期间担任黑石（上海）股权投资管理有限公司北京分公司的高级董事总经理。 傅先生分别于1991年和1988年在北京大学获得历史学硕士学位和历史学学士学位。
Shan Fu,has served as Genetron Holdings Limited director since June 2021. Prior to joining Genetron Holdings Limited Company, Mr. Fu served as joint chief executive officer and the greater China chief executive officer of Vivo Capital LLC since October 2013, prior to which he served as the chief representative of China at Blackstone Group from June 2008 to October 2013. Mr. Fu served as a non-executive director of Sinovac Biotech Ltd., (a company listed on the Nasdaq, symbol: SVA) since July 2018, of TOT BIOPHARM International Company Limited (a company listed on the Stock Exchange, stock code: 1875) since November 2019, and of InnoCare Pharma Limited (a company listed on the Stock Exchange, stock code: 9969) since March 2020. Mr. Fu obatined his bachelor's degree in history from Peking University in Beijing, the PRC in July 1988 and his master's degree in history from Peking University in July 1991. - Shan Fu自业务合并完成以来，一直担任公司董事。 自2013年10月起，傅先生一直担任Vivo Capital LLC的执行合伙人，联席首席执行官和大中华区首席执行官，该公司主要投资于生物技术和医疗保健领域。 诺华生物技术有限公司董事 纳斯达克（Nasdaq）：SVA自2018年7月起担任TOT BIOPHARM International Co.Ltd.的董事。 自2016年1月起（HKSE：01875）担任InnoCare Pharma Ltd.的董事。 自2018年2月（HKSE：09969）开始。傅先生在2008年6月至2013年10月期间担任黑石（上海）股权投资管理有限公司北京分公司的高级董事总经理。 傅先生分别于1991年和1988年在北京大学获得历史学硕士学位和历史学学士学位。
- Shan Fu,has served as Genetron Holdings Limited director since June 2021. Prior to joining Genetron Holdings Limited Company, Mr. Fu served as joint chief executive officer and the greater China chief executive officer of Vivo Capital LLC since October 2013, prior to which he served as the chief representative of China at Blackstone Group from June 2008 to October 2013. Mr. Fu served as a non-executive director of Sinovac Biotech Ltd., (a company listed on the Nasdaq, symbol: SVA) since July 2018, of TOT BIOPHARM International Company Limited (a company listed on the Stock Exchange, stock code: 1875) since November 2019, and of InnoCare Pharma Limited (a company listed on the Stock Exchange, stock code: 9969) since March 2020. Mr. Fu obatined his bachelor's degree in history from Peking University in Beijing, the PRC in July 1988 and his master's degree in history from Peking University in July 1991.
- 阎海
-
阎海，美国杜克大学神经肿瘤讲席教授、病理系终身教授，美国临床医学研究协会会员。研究领域涵盖多种恶性肿瘤发生发展相关驱动基因的发现、突变功能研究与靶向治疗。首次发现了一系列胶质瘤相关的致癌基因 ，如IDH1/IDH2、TERT、CIC、FUBP1、PPM1D、SMARCAL1等，是癌症早期筛查、分子分型、靶向治疗和免疫治疗研究的开拓者。BEAMing技术发明人，该技术已成为如数字PCR等针对游离DNA检测的核心技术，并最早应用于癌症液体活检领域。累计发表SCI论文百余篇，包括《NEJM》、《Science》、《Nature》等国际权威学术期刊，其中在影响因子≥10的期刊发表文章29篇，申请美国专利18项。2014年获得美国癌症研究学会 （AACR） 唯一的科学团队奖， 2017年杜克大学医学院杰出教授奖。美国哥伦比亚大学博士，约翰霍普金斯大学博士后。
Hai Yan,is the Co-Founder and Chief Scientific Officer of Genetron Health. Dr. Yan received his medical degree from Peking University Health Center, Ph.D. degree in Molecular and Cellular Biology Program from Columbia University, and post-doctoral training at The Johns Hopkins University School of Medicine. Dr. Yan was a faculty member at Duke University School of Medicine. He was the Henry S. Friedman Distinguished Professor of Neuro-Oncology, and a Professor of Pathology. He once served as the Director of Neuro Oncology Program at Duke Cancer Institute. He is an elected member of the American Society for Clinical Investigation (ASCI). He was honored as a Damon Runyon Foundation Scholar, an American Cancer Society Scholar, a V Foundation Scholar, and a James S. McDonnell Scholar. He received the 2014 AACR Team Science Award. In 2021, he was awarded the International Prize for Translational Neuroscience from the Gertrud Reemtsma Foundation through the Max Planck Society in Germany. Dr. Yan received his M.D. in basic medicine from Peking University Health Center in 1991 and his Ph.D. degree in molecular and cellular biology from Columbia University in 1997. Dr. Yan also served as research associate at Johns Hopkins University. - 阎海，美国杜克大学神经肿瘤讲席教授、病理系终身教授，美国临床医学研究协会会员。研究领域涵盖多种恶性肿瘤发生发展相关驱动基因的发现、突变功能研究与靶向治疗。首次发现了一系列胶质瘤相关的致癌基因 ，如IDH1/IDH2、TERT、CIC、FUBP1、PPM1D、SMARCAL1等，是癌症早期筛查、分子分型、靶向治疗和免疫治疗研究的开拓者。BEAMing技术发明人，该技术已成为如数字PCR等针对游离DNA检测的核心技术，并最早应用于癌症液体活检领域。累计发表SCI论文百余篇，包括《NEJM》、《Science》、《Nature》等国际权威学术期刊，其中在影响因子≥10的期刊发表文章29篇，申请美国专利18项。2014年获得美国癌症研究学会 （AACR） 唯一的科学团队奖， 2017年杜克大学医学院杰出教授奖。美国哥伦比亚大学博士，约翰霍普金斯大学博士后。
- Hai Yan,is the Co-Founder and Chief Scientific Officer of Genetron Health. Dr. Yan received his medical degree from Peking University Health Center, Ph.D. degree in Molecular and Cellular Biology Program from Columbia University, and post-doctoral training at The Johns Hopkins University School of Medicine. Dr. Yan was a faculty member at Duke University School of Medicine. He was the Henry S. Friedman Distinguished Professor of Neuro-Oncology, and a Professor of Pathology. He once served as the Director of Neuro Oncology Program at Duke Cancer Institute. He is an elected member of the American Society for Clinical Investigation (ASCI). He was honored as a Damon Runyon Foundation Scholar, an American Cancer Society Scholar, a V Foundation Scholar, and a James S. McDonnell Scholar. He received the 2014 AACR Team Science Award. In 2021, he was awarded the International Prize for Translational Neuroscience from the Gertrud Reemtsma Foundation through the Max Planck Society in Germany. Dr. Yan received his M.D. in basic medicine from Peking University Health Center in 1991 and his Ph.D. degree in molecular and cellular biology from Columbia University in 1997. Dr. Yan also served as research associate at Johns Hopkins University.
- Xia Wu
-
Xia Wu从2017年9月开始担任董事。吴女士从2008年7月开始在中金嘉诚投资管理有限公司任职，2012年1月至2014年12月担任副总裁，2015年1月至2019年2月担任执行董事， 自2019年3月起担任董事总经理。她目前是中金康瑞I宁波股权投资有限合伙人（有限合伙）投资委员会成员。 吴女士于2003年在北京大学获得金融学士学位，并于2005年在华威大学的华威商学院获得了经济学和金融硕士学位。
Xia Wu,has served as Genetron Holdings Limited Director since September 2017. Ms. Wu has been serving in CICC Jia Cheng Investment Management Company Limited since July 2008 and has served as vice president from January 2012 to December 2014, as executive director from January 2015 to February 2019, and as managing director since March 2019. She currently serves as a member of the investment committee of CICC Kangrui I (Ningbo) Equity Investment Limited Partners (Limited Partnership) and CICC Kangrui Phase II (Chengdu) Healthcare Venture Capital Partnership (Limited Partnership). Ms. Wu received her bachelor degree in finance from Peking University in 2003 and her master degree in economics and finance from the Warwick Business School of Warwick University in 2005. - Xia Wu从2017年9月开始担任董事。吴女士从2008年7月开始在中金嘉诚投资管理有限公司任职，2012年1月至2014年12月担任副总裁，2015年1月至2019年2月担任执行董事， 自2019年3月起担任董事总经理。她目前是中金康瑞I宁波股权投资有限合伙人（有限合伙）投资委员会成员。 吴女士于2003年在北京大学获得金融学士学位，并于2005年在华威大学的华威商学院获得了经济学和金融硕士学位。
- Xia Wu,has served as Genetron Holdings Limited Director since September 2017. Ms. Wu has been serving in CICC Jia Cheng Investment Management Company Limited since July 2008 and has served as vice president from January 2012 to December 2014, as executive director from January 2015 to February 2019, and as managing director since March 2019. She currently serves as a member of the investment committee of CICC Kangrui I (Ningbo) Equity Investment Limited Partners (Limited Partnership) and CICC Kangrui Phase II (Chengdu) Healthcare Venture Capital Partnership (Limited Partnership). Ms. Wu received her bachelor degree in finance from Peking University in 2003 and her master degree in economics and finance from the Warwick Business School of Warwick University in 2005.
- Dian Kang
-
Dian Kang于2005年至2009年担任深圳发展银行股份有限公司（在深圳证券交易所上市的公司，股票代码：000001）的监事会主席。2001年至2005年担任Springridge Investment Management Limited的董事长。 1994年至2000年担任广东省企业（控股）有限公司副总裁，担任广东证券有限公司和广东省资本控股有限公司董事长，并于1990年至1994年担任中国包装总公司副总裁。 1987年至1990年担任中国农业综合企业信托投资公司总裁，并于1984年至1987年在中国国际信托投资公司海外投资部工作。康先生还曾担任Silver Grant International Industries Limited（于1998年5月至2014年2月在香港联交所上市，股票代码：00171）。康先生毕业于北钢1982年获得钢铁学院的博士学位。他还于1984年获得了中国社会科学院研究生院的经济学硕士学位。
Dian Kang,has served as Genetron Holdings Limited independent director since June 2020. Mr. Kang served as the chief executive officer, and the executive director and the chairman of board of directors of New China Life Insurance Company Ltd. (HKEx: 1336) from 2013 to 2016 and from 2009 to 2016, respectively. Prior to that, he served as chairman of the board of supervisors of Shenzhen Development Bank Company Limited (a company listed on the Shenzhen Stock Exchange, stock code: 000001) from 2005 to 2009, chairman of Springridge Investment Management Limited from 2001 to 2005, director and vice president of the Guangdong Enterprises (Holdings) Limited, chairman of the board of the Guangdong Securities Limited and Guangdong Capital Holdings Ltd. from 1994 to 2000, as well as vice president of China National Packaging Corporation from 1990 to 1994. He also served as vice president of China Agribusiness Trust & Investment Corporation from 1987 to 1990 and worked at the Overseas Investment Department of China International Trust & Investment Corporation from 1984 to 1987. Mr. Kang also served as an independent non-executive director of Silver Grant International Industries Limited (a company listed on the HKSE, stock code: 00171) from May 1998 to February 2014. Mr. Kang graduated from Beijing Steel and Iron Institute in 1982. He also received a master's degree in economics from the Graduate School of the Chinese Academy of Social Sciences in 1984. - Dian Kang于2005年至2009年担任深圳发展银行股份有限公司（在深圳证券交易所上市的公司，股票代码：000001）的监事会主席。2001年至2005年担任Springridge Investment Management Limited的董事长。 1994年至2000年担任广东省企业（控股）有限公司副总裁，担任广东证券有限公司和广东省资本控股有限公司董事长，并于1990年至1994年担任中国包装总公司副总裁。 1987年至1990年担任中国农业综合企业信托投资公司总裁，并于1984年至1987年在中国国际信托投资公司海外投资部工作。康先生还曾担任Silver Grant International Industries Limited（于1998年5月至2014年2月在香港联交所上市，股票代码：00171）。康先生毕业于北钢1982年获得钢铁学院的博士学位。他还于1984年获得了中国社会科学院研究生院的经济学硕士学位。
- Dian Kang,has served as Genetron Holdings Limited independent director since June 2020. Mr. Kang served as the chief executive officer, and the executive director and the chairman of board of directors of New China Life Insurance Company Ltd. (HKEx: 1336) from 2013 to 2016 and from 2009 to 2016, respectively. Prior to that, he served as chairman of the board of supervisors of Shenzhen Development Bank Company Limited (a company listed on the Shenzhen Stock Exchange, stock code: 000001) from 2005 to 2009, chairman of Springridge Investment Management Limited from 2001 to 2005, director and vice president of the Guangdong Enterprises (Holdings) Limited, chairman of the board of the Guangdong Securities Limited and Guangdong Capital Holdings Ltd. from 1994 to 2000, as well as vice president of China National Packaging Corporation from 1990 to 1994. He also served as vice president of China Agribusiness Trust & Investment Corporation from 1987 to 1990 and worked at the Overseas Investment Department of China International Trust & Investment Corporation from 1984 to 1987. Mr. Kang also served as an independent non-executive director of Silver Grant International Industries Limited (a company listed on the HKSE, stock code: 00171) from May 1998 to February 2014. Mr. Kang graduated from Beijing Steel and Iron Institute in 1982. He also received a master's degree in economics from the Graduate School of the Chinese Academy of Social Sciences in 1984.
- Webster Cavenee
-
Webster Cavenee，自2015年以来，他一直担任路德维希癌症研究中心中枢神经系统癌症战略联盟的主管，并自1991年起担任加利福尼亚大学圣地亚哥分校的杰出教授。卡夫尼博士于1985年加入路德维希癌症研究组织，并担任路德维希。 1985年12月至1991年9月在蒙特利尔分公司担任董事。Cavenee博士于1991年9月至2015年6月担任路德维希圣地亚哥分公司董事。在加入路德维希癌症研究之前，Cavenee博士于1977年11月至1983年9月在杰克逊实验室从事博士后工作。麻省理工学院，以及犹他大学霍华德·休斯医学研究所。 Cavenee博士于1983年9月至1985年12月在辛辛那提大学和1985年12月至1991年9月在麦吉尔大学担任教授。Cavenee博士于1973年在堪萨斯州立大学获得微生物学理学学士学位，并获得博士学位。并于1977年获得堪萨斯大学的荣誉。
Webster Cavenee,has served as Genetron Holdings Limited independent director since June 2020. He has served as a director of Strategic Alliances in Central Nervous System Cancers at Ludwig Cancer Research since 2015 and as Distinguished Professor at the University of California San Diego since 1991. Dr. Cavenee joined Ludwig Cancer Research as a member in 1985 and served as Ludwig Montreal branch director from December 1985 to September 1991. Dr. Cavenee served as Ludwig San Diego branch director from September 1991 to June 2015. Prior to joining Ludwig Cancer Research, Dr. Cavenee did postdoctoral work between November 1977 and September 1983 at the Jackson Laboratory, at Massachusetts Institute of Technology, to and the Howard Hughes Medical Institute at the University of Utah. Dr. Cavenee held professorships at the University of Cincinnati from September 1983 to December 1985 and at McGill University from December 1985 to September 1991. Dr. Cavenee received his Bachelor of Science degree in Microbiology from Kansas State University in 1973 and his Ph.D. with honors from the University of Kansas in 1977. - Webster Cavenee，自2015年以来，他一直担任路德维希癌症研究中心中枢神经系统癌症战略联盟的主管，并自1991年起担任加利福尼亚大学圣地亚哥分校的杰出教授。卡夫尼博士于1985年加入路德维希癌症研究组织，并担任路德维希。 1985年12月至1991年9月在蒙特利尔分公司担任董事。Cavenee博士于1991年9月至2015年6月担任路德维希圣地亚哥分公司董事。在加入路德维希癌症研究之前，Cavenee博士于1977年11月至1983年9月在杰克逊实验室从事博士后工作。麻省理工学院，以及犹他大学霍华德·休斯医学研究所。 Cavenee博士于1983年9月至1985年12月在辛辛那提大学和1985年12月至1991年9月在麦吉尔大学担任教授。Cavenee博士于1973年在堪萨斯州立大学获得微生物学理学学士学位，并获得博士学位。并于1977年获得堪萨斯大学的荣誉。
- Webster Cavenee,has served as Genetron Holdings Limited independent director since June 2020. He has served as a director of Strategic Alliances in Central Nervous System Cancers at Ludwig Cancer Research since 2015 and as Distinguished Professor at the University of California San Diego since 1991. Dr. Cavenee joined Ludwig Cancer Research as a member in 1985 and served as Ludwig Montreal branch director from December 1985 to September 1991. Dr. Cavenee served as Ludwig San Diego branch director from September 1991 to June 2015. Prior to joining Ludwig Cancer Research, Dr. Cavenee did postdoctoral work between November 1977 and September 1983 at the Jackson Laboratory, at Massachusetts Institute of Technology, to and the Howard Hughes Medical Institute at the University of Utah. Dr. Cavenee held professorships at the University of Cincinnati from September 1983 to December 1985 and at McGill University from December 1985 to September 1991. Dr. Cavenee received his Bachelor of Science degree in Microbiology from Kansas State University in 1973 and his Ph.D. with honors from the University of Kansas in 1977.
- Wing Kee Lau
-
Wing Kee Lau于2016年4月至2018年6月期间担任完美世界控股有限公司的董事。刘先生于2007年3月至2016年3月担任完美世界有限公司（纳斯达克股票代码：PWRD）的首席财务官。 在加入PWRD之前，刘先生于2004年11月至2007年2月担任北京传媒股份有限公司（香港交易所：1000）的首席财务官兼公司秘书。2000年7月至2004年10月，刘先生担任上海奥美集团财务总监。 玛瑟广告有限公司北京分公司。 刘先生于1990年9月至2000年6月在普华永道香港，上海和北京办事处工作。刘先生于1990年获得香港浸会大学工商管理学士学位，并于2011年获得长江商学院的EMBA学位。他是英国特许公认会计师公会及香港会计师公会会员。
Wing Kee Lau,has served as Ehang Holdings Limited independent director since August 2023. Mr. Lau has served as the chief financial Officer of RoboSense Technology Co., Ltd. (HKSE: 2498) since August 2022. He served as an independent director of Genetron Holdings Limited (NASDAQ: GTH) from June 2020 to March 2024. Mr. Lau served as the chief financial Officer in Tarena International Inc. (NASDAQ: TEDU) from March 2020 to July 2022, the chief financial officer in Square Panda Inc. from July 2018 to August 2019, the chief financial officer in Perfect World Co., Ltd. (SHE: 002624) from March 2007 to June 2018, the chief financial officer and company secretary in Beijing Media Corporation Ltd. (HKSE: 1000) from November 2004 to February 2007, and a financial director in Ogilvy & Mather Advertising Ltd. Beijing Branch from July 2000 to October 2004. Prior to that, Mr. Lau worked in PricewaterhouseCoopers from January 1994 to July 2000. Mr. Lau obtained a bachelor's degree in business administration (finance) from the Hong Kong Baptist University in Hong Kong in November 1990, and an executive master of business administration degree from Cheung Kong Graduate School of Business in China in September 2011. Mr. Lau is an associate of both of The Association of Chartered Certified Accountants and The Hong Kong Institute of Certified Public Accountants. - Wing Kee Lau于2016年4月至2018年6月期间担任完美世界控股有限公司的董事。刘先生于2007年3月至2016年3月担任完美世界有限公司（纳斯达克股票代码：PWRD）的首席财务官。 在加入PWRD之前，刘先生于2004年11月至2007年2月担任北京传媒股份有限公司（香港交易所：1000）的首席财务官兼公司秘书。2000年7月至2004年10月，刘先生担任上海奥美集团财务总监。 玛瑟广告有限公司北京分公司。 刘先生于1990年9月至2000年6月在普华永道香港，上海和北京办事处工作。刘先生于1990年获得香港浸会大学工商管理学士学位，并于2011年获得长江商学院的EMBA学位。他是英国特许公认会计师公会及香港会计师公会会员。
- Wing Kee Lau,has served as Ehang Holdings Limited independent director since August 2023. Mr. Lau has served as the chief financial Officer of RoboSense Technology Co., Ltd. (HKSE: 2498) since August 2022. He served as an independent director of Genetron Holdings Limited (NASDAQ: GTH) from June 2020 to March 2024. Mr. Lau served as the chief financial Officer in Tarena International Inc. (NASDAQ: TEDU) from March 2020 to July 2022, the chief financial officer in Square Panda Inc. from July 2018 to August 2019, the chief financial officer in Perfect World Co., Ltd. (SHE: 002624) from March 2007 to June 2018, the chief financial officer and company secretary in Beijing Media Corporation Ltd. (HKSE: 1000) from November 2004 to February 2007, and a financial director in Ogilvy & Mather Advertising Ltd. Beijing Branch from July 2000 to October 2004. Prior to that, Mr. Lau worked in PricewaterhouseCoopers from January 1994 to July 2000. Mr. Lau obtained a bachelor's degree in business administration (finance) from the Hong Kong Baptist University in Hong Kong in November 1990, and an executive master of business administration degree from Cheung Kong Graduate School of Business in China in September 2011. Mr. Lau is an associate of both of The Association of Chartered Certified Accountants and The Hong Kong Institute of Certified Public Accountants.
- Chao Tang
-
Chao Tang是北京大学物理与系统生物学讲座教授、高级交叉学科研究院执行院长。在他的早期职业生涯中，他在美国期间从事统计物理、凝聚态物理、动力和复杂系统领域的开创性研究。他目前的研究兴趣是物理学和生物学之间的接口，特别是系统生物学和生物物理学。他曾任加州大学旧金山分校终身教授，美国物理学会会士、中国科学院院士、中心创始主任北京大学定量生物学博士，《定量生物学》杂志创始联合主编。他毕业于中国科学技术大学并获得博士学位，芝加哥大学物理学博士学位。
Chao Tang,has served as Genetron Holdings Limited director since June 2021. Dr. Tang served as a chair professor of physics and systems biology and the executive dean of the Academy for Advanced Interdisciplinary Studies at Peking University since October 2011. In his early career, Dr. Tang worked on pioneering research in the fields of statistical physics, condensed matter physics, dynamical and complex systems while in the United States. His current research interest is at the interface between physics and biology, in particular systems biology and biological physics. Dr. Tang was a tenured full professor at the University of California San Francisco from March 2005 to September 2011. Dr. Tang was elected fellow of the American Physical Society in November 1997, and an academician of the Chinese Academy of Sciences in August 2019. He served as the director of the Center for Quantitative Biology at Peking University (formerly known as Center for Theoretical Biology) since September 2001. Dr. Tang served as the co-editor-in-chief of the journal Quantitative Biology from since 2012. Dr. Tang also served as a postdoctoral researcher at the Brookhaven National Laboratory from September 1986 to August 1988, and at the Kavli Institute for Theoretical Physics of the University of California, Santa Barbara from September 1988 to October 1991. Dr. Tang held research positions at NEC Research Institute from October 1991 to March 2005. Dr. Tang obtained his bachelor's degree in mechanics from the University of Science and Technology of China in Hefei, Anhui Province, the PRC in August 1981, and obtained his Ph.D. degree in physics from the University of Chicago in Chicago, the United States in June 1986. - Chao Tang是北京大学物理与系统生物学讲座教授、高级交叉学科研究院执行院长。在他的早期职业生涯中，他在美国期间从事统计物理、凝聚态物理、动力和复杂系统领域的开创性研究。他目前的研究兴趣是物理学和生物学之间的接口，特别是系统生物学和生物物理学。他曾任加州大学旧金山分校终身教授，美国物理学会会士、中国科学院院士、中心创始主任北京大学定量生物学博士，《定量生物学》杂志创始联合主编。他毕业于中国科学技术大学并获得博士学位，芝加哥大学物理学博士学位。
- Chao Tang,has served as Genetron Holdings Limited director since June 2021. Dr. Tang served as a chair professor of physics and systems biology and the executive dean of the Academy for Advanced Interdisciplinary Studies at Peking University since October 2011. In his early career, Dr. Tang worked on pioneering research in the fields of statistical physics, condensed matter physics, dynamical and complex systems while in the United States. His current research interest is at the interface between physics and biology, in particular systems biology and biological physics. Dr. Tang was a tenured full professor at the University of California San Francisco from March 2005 to September 2011. Dr. Tang was elected fellow of the American Physical Society in November 1997, and an academician of the Chinese Academy of Sciences in August 2019. He served as the director of the Center for Quantitative Biology at Peking University (formerly known as Center for Theoretical Biology) since September 2001. Dr. Tang served as the co-editor-in-chief of the journal Quantitative Biology from since 2012. Dr. Tang also served as a postdoctoral researcher at the Brookhaven National Laboratory from September 1986 to August 1988, and at the Kavli Institute for Theoretical Physics of the University of California, Santa Barbara from September 1988 to October 1991. Dr. Tang held research positions at NEC Research Institute from October 1991 to March 2005. Dr. Tang obtained his bachelor's degree in mechanics from the University of Science and Technology of China in Hefei, Anhui Province, the PRC in August 1981, and obtained his Ph.D. degree in physics from the University of Chicago in Chicago, the United States in June 1986.
高管简历
中英对照 | 中文 | 英文- 王思振
王思振具有丰富的跨学科创业经验和企业管理能力，在互联网通信、金融和生物医药行业拥有十八年的经验。曾创立著名企业——iTalkBB，其业务覆盖全球数百万用户，成为北美和澳洲华人地区互联网通讯第一品牌。曾在金融业服务七年，任职公司包括Capital One和 GD Capital。巴黎高等商学院MBA。
Sizhen Wang,is Genetron Holdings Limited co-founder and has served as Genetron Holdings Limited Chief Executive Officer since May 2015. Mr. Wang has served as Genetron Holdings Limited Director since April 2018, and as Genetron Holdings Limited Chairman of the Board since 2021. Prior to founding Genetron Holdings Limited Company, Mr. Wang co-founded iTalkBB in 2004, a company providing voice, TV, data and mobile communication services globally and served as executive vice president until September 2013. He led iTalkBB to enter America's VoIP residential service market and expand its business to Canada, Australia, Singapore and China over eight years and made iTalkBB to become the biggest VoIP and IPTV service provider for overseas Chinese. He previously spent seven years in finance industry, where he gained valuable experience working for Capital One and GD Capital. Mr. Wang received his bachelor's degree in economics from the Central University of Finance and Economics in 1995 and his M.B.A. degree from the HEC Paris School of Management in 2000.- 王思振具有丰富的跨学科创业经验和企业管理能力，在互联网通信、金融和生物医药行业拥有十八年的经验。曾创立著名企业——iTalkBB，其业务覆盖全球数百万用户，成为北美和澳洲华人地区互联网通讯第一品牌。曾在金融业服务七年，任职公司包括Capital One和 GD Capital。巴黎高等商学院MBA。
- Sizhen Wang,is Genetron Holdings Limited co-founder and has served as Genetron Holdings Limited Chief Executive Officer since May 2015. Mr. Wang has served as Genetron Holdings Limited Director since April 2018, and as Genetron Holdings Limited Chairman of the Board since 2021. Prior to founding Genetron Holdings Limited Company, Mr. Wang co-founded iTalkBB in 2004, a company providing voice, TV, data and mobile communication services globally and served as executive vice president until September 2013. He led iTalkBB to enter America's VoIP residential service market and expand its business to Canada, Australia, Singapore and China over eight years and made iTalkBB to become the biggest VoIP and IPTV service provider for overseas Chinese. He previously spent seven years in finance industry, where he gained valuable experience working for Capital One and GD Capital. Mr. Wang received his bachelor's degree in economics from the Central University of Finance and Economics in 1995 and his M.B.A. degree from the HEC Paris School of Management in 2000.
- 徐策
徐策在全球知名投资银行拥有超过十二年的工作经验。2016-2018年担任德意志银行香港投资银行部董事。2010-2016年加入高盛香港投资银行部并最终任职执行董事。2008-2010年任职雷曼兄弟（香港）和野村证券投资银行经理。新加坡国立大学硕士。
Evan Ce Xu,has served as Genetron Holdings Limited Chief Technology Officer since August 2017. From December 2013 to date, Dr. Jiao is also serving as a professor at National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, focusing on the studying of cancer genomics and early diagnosis of cancer. Dr. Jiao's research has been published in multiple renowned academic journals such as Science and Nature Genetics. Dr. Jiao has also received various awards throughout his academic and research careers, including Hans Joaquim Prochaska Research Award, which was awarded by the Johns Hopkins School of Medicine. Dr. Jiao received his M.D. in clinical medicine from Peking Union Medical College in July 2003, and his Ph.D. degree in biological chemistry at the Johns Hopkins University in 2009.- 徐策在全球知名投资银行拥有超过十二年的工作经验。2016-2018年担任德意志银行香港投资银行部董事。2010-2016年加入高盛香港投资银行部并最终任职执行董事。2008-2010年任职雷曼兄弟（香港）和野村证券投资银行经理。新加坡国立大学硕士。
- Evan Ce Xu,has served as Genetron Holdings Limited Chief Technology Officer since August 2017. From December 2013 to date, Dr. Jiao is also serving as a professor at National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, focusing on the studying of cancer genomics and early diagnosis of cancer. Dr. Jiao's research has been published in multiple renowned academic journals such as Science and Nature Genetics. Dr. Jiao has also received various awards throughout his academic and research careers, including Hans Joaquim Prochaska Research Award, which was awarded by the Johns Hopkins School of Medicine. Dr. Jiao received his M.D. in clinical medicine from Peking Union Medical College in July 2003, and his Ph.D. degree in biological chemistry at the Johns Hopkins University in 2009.
- 阎海
阎海，美国杜克大学神经肿瘤讲席教授、病理系终身教授，美国临床医学研究协会会员。研究领域涵盖多种恶性肿瘤发生发展相关驱动基因的发现、突变功能研究与靶向治疗。首次发现了一系列胶质瘤相关的致癌基因 ，如IDH1/IDH2、TERT、CIC、FUBP1、PPM1D、SMARCAL1等，是癌症早期筛查、分子分型、靶向治疗和免疫治疗研究的开拓者。BEAMing技术发明人，该技术已成为如数字PCR等针对游离DNA检测的核心技术，并最早应用于癌症液体活检领域。累计发表SCI论文百余篇，包括《NEJM》、《Science》、《Nature》等国际权威学术期刊，其中在影响因子≥10的期刊发表文章29篇，申请美国专利18项。2014年获得美国癌症研究学会 （AACR） 唯一的科学团队奖， 2017年杜克大学医学院杰出教授奖。美国哥伦比亚大学博士，约翰霍普金斯大学博士后。
Hai Yan,is the Co-Founder and Chief Scientific Officer of Genetron Health. Dr. Yan received his medical degree from Peking University Health Center, Ph.D. degree in Molecular and Cellular Biology Program from Columbia University, and post-doctoral training at The Johns Hopkins University School of Medicine. Dr. Yan was a faculty member at Duke University School of Medicine. He was the Henry S. Friedman Distinguished Professor of Neuro-Oncology, and a Professor of Pathology. He once served as the Director of Neuro Oncology Program at Duke Cancer Institute. He is an elected member of the American Society for Clinical Investigation (ASCI). He was honored as a Damon Runyon Foundation Scholar, an American Cancer Society Scholar, a V Foundation Scholar, and a James S. McDonnell Scholar. He received the 2014 AACR Team Science Award. In 2021, he was awarded the International Prize for Translational Neuroscience from the Gertrud Reemtsma Foundation through the Max Planck Society in Germany. Dr. Yan received his M.D. in basic medicine from Peking University Health Center in 1991 and his Ph.D. degree in molecular and cellular biology from Columbia University in 1997. Dr. Yan also served as research associate at Johns Hopkins University.- 阎海，美国杜克大学神经肿瘤讲席教授、病理系终身教授，美国临床医学研究协会会员。研究领域涵盖多种恶性肿瘤发生发展相关驱动基因的发现、突变功能研究与靶向治疗。首次发现了一系列胶质瘤相关的致癌基因 ，如IDH1/IDH2、TERT、CIC、FUBP1、PPM1D、SMARCAL1等，是癌症早期筛查、分子分型、靶向治疗和免疫治疗研究的开拓者。BEAMing技术发明人，该技术已成为如数字PCR等针对游离DNA检测的核心技术，并最早应用于癌症液体活检领域。累计发表SCI论文百余篇，包括《NEJM》、《Science》、《Nature》等国际权威学术期刊，其中在影响因子≥10的期刊发表文章29篇，申请美国专利18项。2014年获得美国癌症研究学会 （AACR） 唯一的科学团队奖， 2017年杜克大学医学院杰出教授奖。美国哥伦比亚大学博士，约翰霍普金斯大学博士后。
- Hai Yan,is the Co-Founder and Chief Scientific Officer of Genetron Health. Dr. Yan received his medical degree from Peking University Health Center, Ph.D. degree in Molecular and Cellular Biology Program from Columbia University, and post-doctoral training at The Johns Hopkins University School of Medicine. Dr. Yan was a faculty member at Duke University School of Medicine. He was the Henry S. Friedman Distinguished Professor of Neuro-Oncology, and a Professor of Pathology. He once served as the Director of Neuro Oncology Program at Duke Cancer Institute. He is an elected member of the American Society for Clinical Investigation (ASCI). He was honored as a Damon Runyon Foundation Scholar, an American Cancer Society Scholar, a V Foundation Scholar, and a James S. McDonnell Scholar. He received the 2014 AACR Team Science Award. In 2021, he was awarded the International Prize for Translational Neuroscience from the Gertrud Reemtsma Foundation through the Max Planck Society in Germany. Dr. Yan received his M.D. in basic medicine from Peking University Health Center in 1991 and his Ph.D. degree in molecular and cellular biology from Columbia University in 1997. Dr. Yan also served as research associate at Johns Hopkins University.
- 焦宇辰
焦宇辰，中国医学科学院肿瘤医院研究员、博士生导师，长期致力于癌症基因组学及其无创活检技术的研究。完成了胰腺神经内分泌瘤等多种肿瘤的基因组研究，发现了ATRX、TERT等端粒维护相关新基因、新突变，并研究了其在胶质瘤分子分型中的价值，ATRX和TERT均被WHO中枢神经系统肿瘤分型指南列为重要标志物。作为第一或通讯作者在《Science》、《NatureGenetics》、《PNAS》等期刊发表研究论文20余篇。美国约翰霍普金斯大学医学院理学博士，曾在全球著名肿瘤学家BertVogelstein教授团队从事肿瘤基因组及重要癌症基因突变的机制研究。
Yuchen Jiao,has served as Genetron Holdings Limited Chief Technology Officer since August 2017. From December 2013 to date, Dr. Jiao is also serving as a professor at National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, focusing on the studying of cancer genomics and early diagnosis of cancer. Dr. Jiao's research has been published in multiple renowned academic journals such as Science and Nature Genetics. Dr. Jiao has also received various awards throughout his academic and research careers, including Hans Joaquim Prochaska Research Award, which was awarded by the Johns Hopkins School of Medicine. Dr. Jiao received his M.D. in clinical medicine from Peking Union Medical College in July 2003, and his Ph.D. degree in biological chemistry at the Johns Hopkins University in 2009.- 焦宇辰，中国医学科学院肿瘤医院研究员、博士生导师，长期致力于癌症基因组学及其无创活检技术的研究。完成了胰腺神经内分泌瘤等多种肿瘤的基因组研究，发现了ATRX、TERT等端粒维护相关新基因、新突变，并研究了其在胶质瘤分子分型中的价值，ATRX和TERT均被WHO中枢神经系统肿瘤分型指南列为重要标志物。作为第一或通讯作者在《Science》、《NatureGenetics》、《PNAS》等期刊发表研究论文20余篇。美国约翰霍普金斯大学医学院理学博士，曾在全球著名肿瘤学家BertVogelstein教授团队从事肿瘤基因组及重要癌症基因突变的机制研究。
- Yuchen Jiao,has served as Genetron Holdings Limited Chief Technology Officer since August 2017. From December 2013 to date, Dr. Jiao is also serving as a professor at National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, focusing on the studying of cancer genomics and early diagnosis of cancer. Dr. Jiao's research has been published in multiple renowned academic journals such as Science and Nature Genetics. Dr. Jiao has also received various awards throughout his academic and research careers, including Hans Joaquim Prochaska Research Award, which was awarded by the Johns Hopkins School of Medicine. Dr. Jiao received his M.D. in clinical medicine from Peking Union Medical College in July 2003, and his Ph.D. degree in biological chemistry at the Johns Hopkins University in 2009.
- 胡云富
胡云富，首席医疗官，曾在FDA担任要职。里程碑式的批准包括：首例基于NGS的LDT伴随诊断服务（Foundation Medicine 的FoundationFocus CDxBRCA）、首例基于NGS的伴随诊断试剂盒（ThermoFisher Oncomine Dx Target Test）、基于NGS的肿瘤大panel检测服务（纪念斯隆-凯特琳癌症中心的MSK-IMPACT和Foundation Medicine 的FoundationOne CDx）、首例NSCLC液体活检伴随诊断试剂盒（罗氏 Cobas EGFR Mutation Test v2）、FDA目前批准的仅有的两款癌症早筛产品（Exact Sciences的Cologuard和Epigenomics的Epi ProColon）等。他带领的团队因在多项创新产品的首次审批中做出卓越贡献，荣获FDA十余次局级奖励。俄亥俄州立大学兽医生理学与药理学博士及生殖内分泌学硕士；大通福克斯癌症中心博士后。
Yun Fu Hu,has served as Genetron Holdings Limited Chief Medical Officer since 2020. Dr. Hu had more than ten years of service at US Food and Drug Administration ("FDA"), where he had served as Deputy Director and other positions at Division of Molecular Genetics and Pathology, Office of In Vitro Diagnostics and Radiological Health, Center for Device and Radiological Health. During his tenure at FDA, Dr. Hu supervised a staff of scientists, engineers, consumer safety officers and medical officers in premarket reviews and post-market compliance of IVD products and LDTs for genetic testing, molecular cancer diagnostics, companion diagnostics, radio dosimetry, digital pathology and artificial intelligence devices. Some of the notable authorizations by Dr. Hu's group at FDA include: the first NGS-based LDT as CDx (Foundation Medicine FoundationFocus CDxBRCA); the first NGS-based CDx kit (Thermo Fisher Oncomine Dx Target Test); the first NGS-based LDT for tumor profiling (MSK-IMPACT) and later on FoundationOne CDx); the first liquid biopsy test for NSCLC (Roche Cobas EGFR Mutation Test v2); and FDA's only two approved cancer screening tests in the last decade (Exact Sciences' Cologuard and Epigenomics' Epi ProColon). He was a member of the steering committee to stand up the FDA's Oncology Center of Excellence (OCE) under the 21st Century Cures and served as the Center's first Acting Associate Director of In Vitro Diagnostics.Dr. Hu received his bachelor degree from Central China Agricultural University in 1983, his master degree in reproductive endocrinology from the Ohio State University in 1990 and his Ph.D. degree in veterinary physiology & pharmacology from the Ohio State University in 1994 followed by a postdoctoral cancer research fellowship at Fox Chase Cancer Center. Dr. Hu has four US patents and over 30 publications.- 胡云富，首席医疗官，曾在FDA担任要职。里程碑式的批准包括：首例基于NGS的LDT伴随诊断服务（Foundation Medicine 的FoundationFocus CDxBRCA）、首例基于NGS的伴随诊断试剂盒（ThermoFisher Oncomine Dx Target Test）、基于NGS的肿瘤大panel检测服务（纪念斯隆-凯特琳癌症中心的MSK-IMPACT和Foundation Medicine 的FoundationOne CDx）、首例NSCLC液体活检伴随诊断试剂盒（罗氏 Cobas EGFR Mutation Test v2）、FDA目前批准的仅有的两款癌症早筛产品（Exact Sciences的Cologuard和Epigenomics的Epi ProColon）等。他带领的团队因在多项创新产品的首次审批中做出卓越贡献，荣获FDA十余次局级奖励。俄亥俄州立大学兽医生理学与药理学博士及生殖内分泌学硕士；大通福克斯癌症中心博士后。
- Yun Fu Hu,has served as Genetron Holdings Limited Chief Medical Officer since 2020. Dr. Hu had more than ten years of service at US Food and Drug Administration ("FDA"), where he had served as Deputy Director and other positions at Division of Molecular Genetics and Pathology, Office of In Vitro Diagnostics and Radiological Health, Center for Device and Radiological Health. During his tenure at FDA, Dr. Hu supervised a staff of scientists, engineers, consumer safety officers and medical officers in premarket reviews and post-market compliance of IVD products and LDTs for genetic testing, molecular cancer diagnostics, companion diagnostics, radio dosimetry, digital pathology and artificial intelligence devices. Some of the notable authorizations by Dr. Hu's group at FDA include: the first NGS-based LDT as CDx (Foundation Medicine FoundationFocus CDxBRCA); the first NGS-based CDx kit (Thermo Fisher Oncomine Dx Target Test); the first NGS-based LDT for tumor profiling (MSK-IMPACT) and later on FoundationOne CDx); the first liquid biopsy test for NSCLC (Roche Cobas EGFR Mutation Test v2); and FDA's only two approved cancer screening tests in the last decade (Exact Sciences' Cologuard and Epigenomics' Epi ProColon). He was a member of the steering committee to stand up the FDA's Oncology Center of Excellence (OCE) under the 21st Century Cures and served as the Center's first Acting Associate Director of In Vitro Diagnostics.Dr. Hu received his bachelor degree from Central China Agricultural University in 1983, his master degree in reproductive endocrinology from the Ohio State University in 1990 and his Ph.D. degree in veterinary physiology & pharmacology from the Ohio State University in 1994 followed by a postdoctoral cancer research fellowship at Fox Chase Cancer Center. Dr. Hu has four US patents and over 30 publications.
- 张凤玲
张凤玲，自2021年6月起担任Genetron Holdings Limited副总裁。张女士主要负责市场准入和行政事务的管理。张女士自2017年2月起担任Genetron Health的副总裁。她目前还担任广州Genetron生物技术有限公司和广州Genetron医学实验室有限公司的主管。在加入Genetron控股有限公司之前，从1985年8月到1988年12月，她担任China Hewlett-Packard Co., Ltd.的秘书和整体质量管理协调员。随后，她担任Ericsson Communications Co., Ltd.的办公室经理。1988年12月至1992年8月任北京代表处。随后，她于1992年8月至1994年3月在New Power Group北京代表处担任销售经理。之后，她在SRT通信公司担任合同经理。1994年3月至1998年10月担任北京办事处。她于1998年10月加入Shanghai Bell Alcatel Co., Ltd.，并于1998年10月至2013年3月担任销售总监、政府事务总监和副总裁。她于2006年获得复旦大学和香港大学联合项目的工商管理硕士学位。
Fengling Zhang,has served as Genetron Holdings Limited Vice President since June 2021. Ms. Zhang is primarily responsible for the management of market access and administrative affairs. Ms. Zhang has been serving as the vice president of Genetron Health since February 2017. She currently also serves as the supervisor of Guangzhou Genetron Bio-Technology Co., Ltd. and Guangzhou Genetron Medical Laboratory Co., Ltd.Prior to joining Genetron Holdings Limited , Ms. Zhang served as a secretary and the overall quality management coordinator at China Hewlett-Packard Co., Ltd. from August 1985 to December 1988. She then served as the office manager at Ericsson Communications Co., Ltd. Beijing Representative Office from December 1988 to August 1992. Subsequently, she worked as the sales manager at New Power Group Beijing Representative Office from August 1992 to March 1994. After that, she worked as the contract manager at SRT Communications Inc. Beijing Office from March 1994 to October 1998. Ms. Zhang then joined Shanghai Bell Alcatel Co., Ltd. in October 1998 and served as the sales director, director of government affairs and the vice president from October 1998 to March 2013. Ms. Zhang received her M.B.A. degree from Fudan University and Hong Kong University Joint Program in 2006.- 张凤玲，自2021年6月起担任Genetron Holdings Limited副总裁。张女士主要负责市场准入和行政事务的管理。张女士自2017年2月起担任Genetron Health的副总裁。她目前还担任广州Genetron生物技术有限公司和广州Genetron医学实验室有限公司的主管。在加入Genetron控股有限公司之前，从1985年8月到1988年12月，她担任China Hewlett-Packard Co., Ltd.的秘书和整体质量管理协调员。随后，她担任Ericsson Communications Co., Ltd.的办公室经理。1988年12月至1992年8月任北京代表处。随后，她于1992年8月至1994年3月在New Power Group北京代表处担任销售经理。之后，她在SRT通信公司担任合同经理。1994年3月至1998年10月担任北京办事处。她于1998年10月加入Shanghai Bell Alcatel Co., Ltd.，并于1998年10月至2013年3月担任销售总监、政府事务总监和副总裁。她于2006年获得复旦大学和香港大学联合项目的工商管理硕士学位。
- Fengling Zhang,has served as Genetron Holdings Limited Vice President since June 2021. Ms. Zhang is primarily responsible for the management of market access and administrative affairs. Ms. Zhang has been serving as the vice president of Genetron Health since February 2017. She currently also serves as the supervisor of Guangzhou Genetron Bio-Technology Co., Ltd. and Guangzhou Genetron Medical Laboratory Co., Ltd.Prior to joining Genetron Holdings Limited , Ms. Zhang served as a secretary and the overall quality management coordinator at China Hewlett-Packard Co., Ltd. from August 1985 to December 1988. She then served as the office manager at Ericsson Communications Co., Ltd. Beijing Representative Office from December 1988 to August 1992. Subsequently, she worked as the sales manager at New Power Group Beijing Representative Office from August 1992 to March 1994. After that, she worked as the contract manager at SRT Communications Inc. Beijing Office from March 1994 to October 1998. Ms. Zhang then joined Shanghai Bell Alcatel Co., Ltd. in October 1998 and served as the sales director, director of government affairs and the vice president from October 1998 to March 2013. Ms. Zhang received her M.B.A. degree from Fudan University and Hong Kong University Joint Program in 2006.